Search Results - "Bohlen, Stefan"

Cross-Species Single-Cell Analysis Reveals Divergence of the Primate Microglia Program by Geirsdottir, Laufey, David, Eyal, Keren-Shaul, Hadas, Weiner, Assaf, Bohlen, Stefan Cornelius, Neuber, Jana, Balic, Adam, Giladi, Amir, Sheban, Fadi, Dutertre, Charles-Antoine, Pfeifle, Christine, Peri, Francesca, Raffo-Romero, Antonella, Vizioli, Jacopo, Matiasek, Kaspar, Scheiwe, Christian, Meckel, Stephan, Mätz-Rensing, Kerstin, van der Meer, Franziska, Thormodsson, Finnbogi Rutur, Stadelmann, Christine, Zilkha, Noga, Kimchi, Tali, Ginhoux, Florent, Ulitsky, Igor, Erny, Daniel, Amit, Ido, Prinz, Marco

“…Microglia, the brain-resident immune cells, are critically involved in many physiological and pathological brain processes, including neurodegeneration. Here…”
Get full text

Survival from Rhino-Orbital-Cerebral Mucormycosis in SARS-CoV-2-Positive Diabetic Patients: Two Case Reports by Lädrach, Claudia, Wartenberg, Martin, Zimmerli, Stefan, Anschuetz, Lukas, Bohlen, Stefan, Ebner, Julian, de Gouyon Matignon de Pontouraude, Claire M.F., Caversaccio, Marco, Wagner, Franca

“…Abstract Introduction: Rhino-orbital-cerebral mucormycosis (ROCM) is a rare angioinvasive fungal infection known to be associated with high morbidity and over…”
Get full text

Grasping premanifest Huntington's disease - shaping new endpoints for new trials by Reilmann, Ralf, Bohlen, Stefan, Klopstock, Thomas, Bender, Andreas, Weindl, Adolf, Saemann, Philipp, Auer, Dorothee P., Ringelstein, Erich B., Lange, Herwig W.

“…Future clinical trials in subjects with premanifest Huntington's disease (preHD) may depend on the availability of biomarkers. It was previously shown in…”
Get full text

Tongue force analysis assesses motor phenotype in premanifest and symptomatic Huntington's disease by Reilmann, Ralf, Bohlen, Stefan, Klopstock, Thomas, Bender, Andreas, Weindl, Adolf, Saemann, Philipp, Auer, Dorothee P., Ringelstein, E. Bernd, Lange, Herwig W.

“…Motor symptoms in Huntington's Disease (HD) are commonly assessed by the Unified Huntington's Disease Rating Scale‐Total Motor Score (UHDRS‐TMS). However, the…”
Get full text

Cross-Species Single-Cell Analysis Reveals Divergence of the Primate Microglia Program by Geirsdottir, Laufey, David, Eyal, Keren-Shaul, Hadas, Weiner, Assaf, Bohlen, Stefan Cornelius, Neuber, Jana, Balic, Adam, Giladi, Amir, Sheban, Fadi, Dutertre, Charles-Antoine, Pfeifle, Christine, Peri, Francesca, Raffo-Romero, Antonella, Vizioli, Jacopo, Matiasek, Kaspar, Scheiwe, Christian, Meckel, Stephan, Mätz-Rensing, Kerstin, van der Meer, Franziska, Thormodsson, Finnbogi Rutur, Stadelmann, Christine, Zilkha, Noga, Kimchi, Tali, Ginhoux, Florent, Ulitsky, Igor, Erny, Daniel, Amit, Ido, Prinz, Marco

Get full text

F06 When and how does manifest hd begin? a comparison of age at onset of motor and non-motor symptoms by Lange, Herwig, Bohlen, Stefan, Reilmann, Ralf

“…BackgroundIn his classical paper, George Huntington described movement disorder and psychiatric symptoms. In 1915, Davenport described ‘a biotype in which the…”
Get full text

On the rise: Quantitative measures in Huntington's disease by Reilmann, Ralf, Schubert, Robin, Bohlen, Stefan, Sass, Christian

Get full text

Safety and efficacy of pridopidine in patients with Huntington's disease (PRIDE-HD): a phase 2, randomised, placebo-controlled, multicentre, dose-ranging study by Reilmann, Ralf, Grachev, Igor D, Savola, Juha-Matti, Borowsky, Beth, Eyal, Eli, Gross, Nicholas, Langbehn, Douglas, Schubert, Robin, Wickenberg, Anna Teige, Papapetropoulos, Spyros, Squitieri, Ferdinando, Kieburtz, Karl, Landwehrmeyer, G Bernhard, Agarwal, Pinky, Anderson, Karen E, Aziz, Nasir A, Azulay, Jean-Phillippe, Bachoud-Levi, Anne C, Barker, Roger, Bebak, Agnieszka, Beuth, Markus, Biglan, Kevin, Blin, Stephanie, Bonelli, Raphael, Caldwell, Sue, Calvas, Fabienne, Carlos, Jonielyn, Chong, Terrence, Chua, Phyllis, Coleman, Allison, Corey-Bloom, Jody, Cousins, Rebecca, Craufurd, David, De Michele, Giuseppe, Dornhege, Laura, Feigin, Andrew, Gallehawk, Stephanie, Gauteul, Pascale, Gonzales, Carey, Griffith, Jane, Guttman, Mark, Heim, Beatrix, Heller, Hope, Hjermind, Lena, Ivanko, Larry, Jaynes, Jessica, Jenckes, Mollie, Kaminski, Barbara, Kampstra, Anne, Konkel, Agnieszka, Kopishinskaya, Svetlana, Krystkowiak, Pierre, Komati, Suresh K, Lakoning, Stefan, Latipova, Guzal, Leavitt, Blair, Loy, Clement, Madsen, Louise, Marder, Karen, Mason, Sarah, Mendis, Neila, Mendis, Tilak, Norris, Virginia, Olivier, Audrey, Orth, Michael, Owens, Ashley, Panegyres, Peter, Perlman, Susan, Preston, Joy, Puch, Alicja, Rialland, Amandine, Rickards, Hugh, Romoli, Anna M, Ross, Christopher, Rosser, Anne, Rudzinska, Monika, Russo, Cinzina V, Saft, Carsten, Segro, Victoria, Seppi, Klaus, Shannon, Barbara, Shprecher, David, Simonin, Clemence, Skitt, Zara, Soliveri, Paola, Squitieri, Ferdinando, Suski, Valarie, Stepniak, Iwona, Sungmee, Park, Temirbaeva, Sofia, Uhl, Stefanie, Vangsted-Hansen, Christina, Verny, Christophe, Wall, Paola, Walker, Francis, Wasserman, Paula, Witkowski, Grzegorz, Wright, Jan, Zalyalova, Zuleykha, Zielonka, Daniel

“…Previous trials have shown that pridopidine might reduce motor impairment in patients with Huntington's disease. The aim of this study was to ascertain whether…”
Get full text

Gait variability as digital biomarker of disease severity in Huntington’s disease by Gaßner, Heiko, Jensen, Dennis, Marxreiter, F., Kletsch, Anja, Bohlen, Stefan, Schubert, Robin, Muratori, Lisa M., Eskofier, Bjoern, Klucken, Jochen, Winkler, Jürgen, Reilmann, Ralf, Kohl, Zacharias

“…Background Impaired gait plays an important role for quality of life in patients with Huntington’s disease (HD). Measuring objective gait parameters in HD…”
Get full text

J07 What can we learn from a phase ii study with BN82451B in hd beyond safety and tolerability – clinical versus objective motor measures by Bohlen, Stefan, Paty, Isabelle, Volteau, Magali, Meyer, Ingo, Rein, Werner, Kosinski, Christoph, Reilmann, Ralf

“…BackgroundPreclinical research indicates that BN82451B has potential to interfere with excitotoxicity, and possesses antioxidant, anti-inflammatory, and…”
Get full text

Objective assessment of gait and posture in premanifest and manifest Huntington disease — A multi-center study by Beckmann, Heike, Bohlen, Stefan, Saft, Carsten, Hoffmann, Rainer, Gerss, Joachim, Muratori, Lisa, Ringelstein, E. Bernd, Landwehrmeyer, G. Bernhard, Reilmann, Ralf

“…•Objective and quantitative measures of posture and gait are sensitive in HD.•Posturography and GAITRite® were applied in manifest and premanifest…”
Get full text

A longitudinal study of magnetic resonance spectroscopy Huntington's disease biomarkers by Sturrock, Aaron, Laule, Corree, Wyper, Katy, Milner, Ruth A., Decolongon, Joji, Santos, Rachelle Dar, Coleman, Allison J., Carter, Kimberley, Creighton, Susan, Bechtel, Natalie, Bohlen, Stefan, Reilmann, Ralf, Johnson, Hans J., Hayden, Michael R., Tabrizi, Sarah J., Mackay, Alex L., Leavitt, Blair R.

“…Putaminal metabolites examined using cross‐sectional magnetic resonance spectroscopy (MRS) can distinguish pre‐manifest and early Huntington's Disease (HD)…”
Get full text

The impact of occipital lobe cortical thickness on cognitive task performance: An investigation in Huntington's Disease by Johnson, Eileanoir B., Rees, Elin M., Labuschagne, Izelle, Durr, Alexandra, Leavitt, Blair R., Roos, Raymund A.C., Reilmann, Ralf, Johnson, Hans, Hobbs, Nicola Z., Langbehn, Douglas R., Stout, Julie C., Tabrizi, Sarah J., Scahill, Rachael I.

“…The occipital lobe is an important visual processing region of the brain. Following consistent findings of early neural changes in the occipital lobe in…”
Get full text

Assessment of involuntary choreatic movements in Huntington's disease-Toward objective and quantitative measures by Reilmann, Ralf, Bohlen, Stefan, Kirsten, Florian, Ringelstein, E. Bernd, Lange, Herwig W.

“…Objective measures of motor impairment may improve the sensitivity and reliability of motor end points in clinical trials. In Huntington's disease, involuntary…”
Get full text

Correction to: Gait variability as digital biomarker of disease severity in Huntington’s disease by Gaßner, Heiko, Jensen, Dennis, Marxreiter, Franz, Kletsch, Anja, Bohlen, Stefan, Schubert, Robin, Muratori, Lisa M., Eskofier, Bjoern, Klucken, Jochen, Winkler, Jürgen, Reilmann, Ralf, Kohl, Zacharias

“…The original version of this article unfortunately contained a mistake. The name of one author is not presented correctly in the author group…”
Get full text

M4 Safety and tolerability of BN82451B in huntington’s disease by Bohlen, Stefan, Mühlbäck, Alzbeta, Marquard, Ralf, Saß, Christian, Reetz, Katrin, Schiefer, Johannes, Saft, Carsten, Kohl, Zacharias, Bonelli, Raphael, Münchau, Alexander, Klebe, Stephan, Weindl, Adolf, Storch, Alexander, Löhle, Matthias, Klopstock, Thomas, Schöls, Ludger, Seppi, Klaus, Boelmans, Kai, Schubert, Robin, Brisset, Carine, Meyer, Ingo, Schaumann, Frank, Rein, Werner, Poitout, Lydie, Paty, Isabelle, Reilmann, Ralf

“…BackgroundBN82451B is a small, orally active molecule with good CNS penetration. Preclinical studies in tgHD R6/2 mice suggested improved motor function and…”
Get full text

Intellectual enrichment and genetic modifiers of cognition and brain volume in Huntington's disease by Papoutsi, Marina, Flower, Michael, Hensman Moss, Davina J, Holmans, Peter, Estevez-Fraga, Carlos, Johnson, Eileanoir B, Scahill, Rachael I, Rees, Geraint, Langbehn, Douglas, Tabrizi, Sarah J

“…An important step towards the development of treatments for cognitive impairment in ageing and neurodegenerative diseases is to identify genetic and…”
Get full text

Corpus callosal atrophy in premanifest and early Huntington's disease by Crawford, Helen E, Hobbs, Nicola Z, Keogh, Ruth, Langbehn, Douglas R, Frost, Chris, Johnson, Hans, Landwehrmeyer, Bernhard, Reilmann, Ralf, Craufurd, David, Stout, Julie C, Durr, Alexandra, Leavitt, Blair R, Roos, Raymund A C, Tabrizi, Sarah J, Scahill, Rachael I

“…Volumetric MRI studies have highlighted the pronounced loss of white matter in premanifest and early Huntington's Disease (HD). The current study focussed on…”
Get more information

FDG μPET Fails to Detect a Disease-Specific Phenotype in Rats Transgenic for Huntington's Disease – A 15 Months Follow-up Study by Reilmann, Ralf, Lippross, Veronika, Hölzner, Eva, Gigengack, Fabian, Bohlen, Stefan, Kugel, Harald, Deppe, Michael, Osada, Nani, Lücke, M, Riess, Olaf, Nguyen, Huu Phuc, Von Hörsten, Stephan, Schäfers, Klaus, Schäfers, Michael, Jacobs, Andreas H, Hermann, Sven

“…FDG-PET detects hypometabolism in premanifest and symptomatic Huntington's disease (HD). A cross-sectional study suggested that whole-brain FDG-PET is capable…”
Get more information

NMDA receptor gene variations as modifiers in Huntington disease: a replication study by Saft, Carsten, Epplen, Jörg T, Wieczorek, Stefan, Landwehrmeyer, G Bernhard, Roos, Raymund A C, de Yebenes, Justo Garcia, Dose, Matthias, Tabrizi, Sarah J, Craufurd, David, Arning, Larissa

“…Several candidate modifier genes which, in addition to the pathogenic CAG repeat expansion, influence the age at onset (AO) in Huntington disease (HD) have…”
Get full text